Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| Yesterday 4:34 PM View:  | Jordan Erica Chief Commercial Officer | Revance Therapeutics, Inc. (RVNC) | 16-Apr-24 | Sale | 2,392 | $3.80 | $9,096.30 | (2%) 117.26K to 114.86K | |
| 19-Mar-24 6:44 PM View: | Moxie Dwight CLO & GC | Revance Therapeutics, Inc. (RVNC) | 18-Mar-24 | Sale | 8,125 | $5.04 | $40,971.10 | (6%) 145.94K to 137.81K | |
| 19-Mar-24 6:44 PM View: | Schilke Tobin CFO | Revance Therapeutics, Inc. (RVNC) | 18-Mar-24 | Sale | 9,361 | $5.04 | $47,203.80 | (5%) 202.03K to 192.67K | |
| 19-Mar-24 6:45 PM View: | Sjuts Dustin S President | Revance Therapeutics, Inc. (RVNC) | 18-Mar-24 | Sale | 9,211 | $5.04 | $46,446.50 | (5%) 176.76K to 167.55K | |
| 19-Mar-24 6:44 PM View: | Moxie Dwight CLO & GC | Revance Therapeutics, Inc. (RVNC) | 15-Mar-24 | Payment of Exercise | 3,269 | $5.30 | $17,342.00 | (2%) 149.21K to 145.94K | |
| 19-Mar-24 6:44 PM View: | Schilke Tobin CFO | Revance Therapeutics, Inc. (RVNC) | 15-Mar-24 | Payment of Exercise | 3,822 | $5.30 | $20,275.70 | (2%) 205.85K to 202.03K | |
| 19-Mar-24 6:43 PM View: | Foley Mark J CEO Director | Revance Therapeutics, Inc. (RVNC) | 15-Mar-24 | Payment of Exercise | 20,533 | $5.30 | $108,928.00 | (2%) 1.13M to 1.11M | |
| 19-Mar-24 6:45 PM View: | Sjuts Dustin S President | Revance Therapeutics, Inc. (RVNC) | 15-Mar-24 | Payment of Exercise | 2,967 | $5.30 | $15,739.90 | (2%) 179.73K to 176.76K | |
| 08-Mar-24 4:33 PM View: | Foley Mark J CEO Director | Revance Therapeutics, Inc. (RVNC) | 06-Mar-24 | Private Purchase | 30,000 | $6.98 | $209,400.00 | 3% 1.1M to 1.13M | |
| 04-Mar-24 5:34 PM View: | Sjuts Dustin S President | Revance Therapeutics, Inc. (RVNC) | 29-Feb-24 | Grant | 22,110 | -- | -- | 14% 157.62K to 179.73K | |
| 04-Mar-24 4:33 PM View: | Foley Mark J CEO Director | Revance Therapeutics, Inc. (RVNC) | 29-Feb-24 | Grant | 70,750 | -- | -- | 7% 1.03M to 1.1M | |
| 04-Mar-24 5:33 PM View: | Moxie Dwight CLO & GC | Revance Therapeutics, Inc. (RVNC) | 29-Feb-24 | Grant | 15,143 | -- | -- | 11% 134.07K to 149.21K | |
| 04-Mar-24 4:44 PM View: | Schilke Tobin CFO | Revance Therapeutics, Inc. (RVNC) | 29-Feb-24 | Grant | 17,447 | -- | -- | 9% 188.4K to 205.85K | |
| 02-Feb-24 4:48 PM View: | Moxie Dwight SVP, GC & Secretary | Revance Therapeutics, Inc. (RVNC) | 31-Jan-24 | Grant | 90,000 | -- | -- | 204% 44.07K to 134.07K | |
| 02-Feb-24 4:46 PM View: | Schilke Tobin CFO | Revance Therapeutics, Inc. (RVNC) | 31-Jan-24 | Grant | 96,667 | -- | -- | 105% 91.73K to 188.4K | |
| 03-Jan-24 4:48 PM View: | Schilke Tobin CFO | Revance Therapeutics, Inc. (RVNC) | 31-Dec-23 | Grant | 434 | $7.47 | $3,241.98 | < 1% 91.3K to 91.73K | |
| 03-Jan-24 4:47 PM View: | Foley Mark J CEO Director | Revance Therapeutics, Inc. (RVNC) | 31-Dec-23 | Grant | 264 | $7.47 | $1,972.08 | < 1% 1.03M to 1.03M | |
| 03-Jan-24 4:50 PM View: | Sjuts Dustin S President | Revance Therapeutics, Inc. (RVNC) | 31-Dec-23 | Grant | 264 | $7.47 | $1,972.08 | < 1% 157.35K to 157.62K | |
| 18-Dec-23 4:32 PM View: | Sjuts Dustin S President | Revance Therapeutics, Inc. (RVNC) | 15-Dec-23 | Payment of Exercise | 4,712 | $8.08 | $38,073.00 | (3%) 162.07K to 157.35K | |
| 07-Sep-23 5:37 PM View: | Moxie Dwight SVP, GC & Secretary | Revance Therapeutics, Inc. (RVNC) | 06-Sep-23 | Sale (Planned) | 11,000 | $17.06 | $187,704.00 | (20%) 55.07K to 44.07K | |
| 07-Sep-23 5:37 PM View: | Moxie Dwight SVP, GC & Secretary | Revance Therapeutics, Inc. (RVNC) | 05-Sep-23 | Private Sale (Planned) | 23,853 | $17.81 | $424,920.00 | (30%) 78.92K to 55.07K | |
| 15-Aug-23 4:16 PM View: | Schilke Tobin CFO | Revance Therapeutics, Inc. (RVNC) | 11-Aug-23 | Payment of Exercise | 11,215 | $18.91 | $212,076.00 | (11%) 102.52K to 91.3K | |
| 15-Aug-23 4:15 PM View: | Sjuts Dustin S President | Revance Therapeutics, Inc. (RVNC) | 11-Aug-23 | Grant | 22,620 | -- | -- | 15% 148.35K to 170.97K | |
| 15-Aug-23 4:15 PM View: | Foley Mark J CEO Director | Revance Therapeutics, Inc. (RVNC) | 11-Aug-23 | Grant | 122,143 | -- | -- | 13% 951.29K to 1.07M | |
| 15-Aug-23 4:15 PM View: | Sjuts Dustin S President | Revance Therapeutics, Inc. (RVNC) | 11-Aug-23 | Payment of Exercise | 8,901 | $18.91 | $168,318.00 | (5%) 170.97K to 162.07K | |
| 15-Aug-23 4:15 PM View: | Moxie Dwight SVP, GC & Secretary | Revance Therapeutics, Inc. (RVNC) | 11-Aug-23 | Grant | 19,346 | -- | -- | 28% 69.17K to 88.51K | |
| 15-Aug-23 4:15 PM View: | Foley Mark J CEO Director | Revance Therapeutics, Inc. (RVNC) | 11-Aug-23 | Payment of Exercise | 48,064 | $18.91 | $908,890.00 | (4%) 1.07M to 1.03M | |
| 15-Aug-23 4:16 PM View: | Schilke Tobin CFO | Revance Therapeutics, Inc. (RVNC) | 11-Aug-23 | Grant | 22,620 | -- | -- | 28% 79.9K to 102.52K | |
| 15-Aug-23 4:15 PM View: | Moxie Dwight SVP, GC & Secretary | Revance Therapeutics, Inc. (RVNC) | 11-Aug-23 | Payment of Exercise | 9,592 | $18.91 | $181,385.00 | (11%) 88.51K to 78.92K | |
| 04-Aug-23 5:07 PM View: | Foley Mark J CEO Director | Revance Therapeutics, Inc. (RVNC) | 03-Aug-23 | Private Sale (Planned) | 26,279 | $22.57 | $593,151.00 | (3%) 977.57K to 951.29K | |
| 05-Jul-23 10:00 PM View: | Foley Mark J CEO Director | Revance Therapeutics, Inc. (RVNC) | 03-Jul-23 | Private Sale (Planned) | 26,279 | $24.94 | $655,333.00 | (3%) 1.0M to 977.57K | |
| 05-Jul-23 10:00 PM View: | Schilke Tobin CFO | Revance Therapeutics, Inc. (RVNC) | 03-Jul-23 | Private Sale (Planned) | 1,701 | $25.04 | $42,593.00 | (2%) 81.6K to 79.9K | |
| 05-Jul-23 10:00 PM View: | Schilke Tobin CFO | Revance Therapeutics, Inc. (RVNC) | 30-Jun-23 | Grant | 769 | $15.61 | $12,001.00 | < 1% 80.83K to 81.6K | (1%) |
| 05-Jul-23 10:00 PM View: | Sjuts Dustin S President | Revance Therapeutics, Inc. (RVNC) | 30-Jun-23 | Grant | 1,000 | $15.61 | $15,606.00 | < 1% 147.35K to 148.35K | (1%) |
| 05-Jul-23 10:00 PM View: | Foley Mark J CEO Director | Revance Therapeutics, Inc. (RVNC) | 30-Jun-23 | Grant | 1,000 | $15.61 | $15,606.00 | < 1% 1.0M to 1.0M | (1%) |
| 20-Jun-23 4:25 PM View: | Kolaja Carey Oconnor Director | Revance Therapeutics, Inc. (RVNC) | 15-Jun-23 | Option Exercise | 2,500 | $18.12 | $45,300.00 | 15% 16.56K to 19.06K | |
| 20-Jun-23 4:25 PM View: | Kolaja Carey Oconnor Director | Revance Therapeutics, Inc. (RVNC) | 15-Jun-23 | Planned Option Sale | 2,500 | $28.24 | $70,600.00 | (13%) 19.06K to 16.56K | |
| 13-Jun-23 10:00 PM View: | Sjuts Dustin S President | Revance Therapeutics, Inc. (RVNC) | 09-Jun-23 | Private Sale (Planned) | 5,000 | $30.82 | $154,096.00 | (3%) 152.35K to 147.35K | |
| 13-Jun-23 10:00 PM View: | Foley Mark J CEO Director | Revance Therapeutics, Inc. (RVNC) | 09-Jun-23 | Private Sale (Planned) | 31,279 | $30.72 | $960,928.00 | (3%) 1.03M to 1.0M | |
| 05-Jun-23 6:06 PM View: | Schilke Tobin CFO | Revance Therapeutics, Inc. (RVNC) | 02-Jun-23 | Sale (Planned) | 500 | $31.00 | $15,500.00 | (< 1%) 81.33K to 80.83K | |
| 05-Jun-23 6:06 PM View: | Schilke Tobin CFO | Revance Therapeutics, Inc. (RVNC) | 01-Jun-23 | Private Sale (Planned) | 2,701 | $30.57 | $82,569.60 | (3%) 84.03K to 81.33K | |
| 16-May-23 8:29 PM View: | Moxie Dwight SVP, GC & Secretary | Revance Therapeutics, Inc. (RVNC) | 15-May-23 | Sale | 21,401 | $34.55 | $739,338.00 | (24%) 90.57K to 69.17K | |
| 16-May-23 8:29 PM View: | Schilke Tobin CFO | Revance Therapeutics, Inc. (RVNC) | 15-May-23 | Sale | 21,401 | $34.55 | $739,338.00 | (20%) 105.43K to 84.03K | |
| 16-May-23 8:29 PM View: | Sjuts Dustin S President | Revance Therapeutics, Inc. (RVNC) | 15-May-23 | Sale | 21,015 | $34.55 | $726,003.00 | (12%) 173.36K to 152.35K | |
| 16-May-23 8:29 PM View: | Foley Mark J CEO Director | Revance Therapeutics, Inc. (RVNC) | 15-May-23 | Sale | 70,447 | $34.55 | $2,433,730.00 | (6%) 1.1M to 1.03M | |
| 05-May-23 5:14 PM View: | Kolaja Carey Oconnor Director | Revance Therapeutics, Inc. (RVNC) | 03-May-23 | Grant | 3,534 | -- | -- | 27% 13.03K to 16.56K | |
| 05-May-23 5:15 PM View: | Ware Olivia C Director | Revance Therapeutics, Inc. (RVNC) | 03-May-23 | Grant | 3,534 | -- | -- | 27% 13.14K to 16.68K | |
| 05-May-23 5:14 PM View: | Nolet Chris Director | Revance Therapeutics, Inc. (RVNC) | 03-May-23 | Grant | 3,534 | -- | -- | 14% 25.07K to 28.61K | |
| 05-May-23 5:15 PM View: | Gangolli Julian S Director | Revance Therapeutics, Inc. (RVNC) | 03-May-23 | Grant | 3,534 | -- | -- | 13% 26.57K to 30.11K | |
| 05-May-23 5:13 PM View: | Beraud Jill Director | Revance Therapeutics, Inc. (RVNC) | 03-May-23 | Grant | 3,534 | -- | -- | 14% 25.07K to 28.61K |
